HARRISBURG, PA – June 24, 2026 – Senator Lisa Boscola (D-Northampton) announced the Pennsylvania Senate today unanimously approved Senate Bill 1206, legislation that will modernize the Commonwealth’s pharmaceutical manufacturer licensure process and strengthen Pennsylvania’s ability to compete for life sciences jobs and investment.
Under current law, pharmaceutical manufacturers must complete the federal Food and Drug Administration approval process in full before applying for a Pennsylvania state license. A sequencing requirement that leaves the Commonwealth unprepared to act the moment federal approval is granted, allowing competitor states to move faster and capture investment.
SB 1206 eliminates that bottleneck by allowing manufacturers to pursue state licensure concurrently with the FDA process. The bill makes no changes to federal safety standards or approval requirements. It simply ensures Pennsylvania is ready to license a manufacturer the moment federal approval comes through, rather than starting from scratch afterward.
“Pennsylvania has world-class research institutions and a growing life sciences sector, and we should be doing everything we can to keep that investment here and attract more of it,” said Senator Boscola. “This bill doesn’t cut corners on safety, it cuts unnecessary red tape. While we waited, competitor states were already moving. Today, we’re catching up, and we’re sending a clear signal that Pennsylvania is open for business.”
SB 1206 was prime-sponsored by Senator Tracy Pennycuick (R-Montgomery) and co-sponsored by Senator Kristin Phillips-Hill (R-York). The bill now moves to the House of Representatives for consideration.
###